US-India IPR spat puts spotlight back on 3(d) and TRIPS divide
This article was originally published in Scrip
Escalating tensions between the US and India over intellectual property rights (IPR) issues have put the spotlight back on provisions such as the controversial Section 3(d) of India's Patent Act and the differing views of the developed and developing world on obligations under TRIPS (the Agreement on Trade-Related Aspects of Intellectual Property Rights).
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.